Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy

Area of Science:

• Oncology
• Genetics
• Epigenetics

Background:

• Current cancer drug treatments often focus on single molecular targets, yielding limited clinical success.
• Despite promising experimental models, these targeted therapies struggle with the heterogeneity of most cancers.

Purpose of the Study:

• To review the challenges in cancer drug therapy stemming from genetic and epigenetic heterogeneity.
• To discuss novel therapeutic strategies and future research directions in cancer treatment.

Main Methods:

• Literature review of gene and pathway-centric cancer treatment approaches.
• Discussion of genome theory to understand and target bio-heterogeneity.
• Exploration of emerging targets like epigenetics, metabolism, and tumor microenvironment.

Main Results:

• Traditional targeted therapies face significant limitations due to intra-tumor heterogeneity.
• New approaches targeting epigenetics, metabolism, and genome instability show potential but require further validation.
• Monitoring and targeting genome-level heterogeneity is crucial for therapeutic success.

Conclusions:

• Cancer drug therapy faces persistent challenges due to multi-level genetic and epigenetic heterogeneity.
• Future research must focus on understanding and addressing this complexity for improved treatment outcomes.
• Integrating insights from genome theory and novel therapeutic targets is essential for advancing cancer care.